Sanofi (SNY) stock
SNY · Sanofi · NASDAQ
- Market cap
- $113.47B
- Shares out
- 2.44B
What is the latest news on SNY stock?
SNY rose 1.01% to $46.52 on Nov 20, 2026. No SNY story in the last two days; the most recent is below.
Submission status for GENZYME CORP A SANOFI CO's drug INFILBRAY (ORIG-1) with active ingredient VENGLUSTAT has changed to 'Approval' on 11/18/2026. Application Category: NDA, Application Number: 221144, Application Classification: Type 1 - New Molecular Entity
All SNY newsWhen does Sanofi report earnings?
The latest Sanofi earnings release came out on Jun 2, 2025: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology. Before that, Sanofi reported on May 13, 2024.
SNY earnings historyWho owns the most SNY stock?
Dodge & Cox was the largest reported holder of SNY at the end of Q2 2026, with 28,088,274 shares worth $1.2 billion. Next came Morgan Stanley ($456.6 million) and Fisher Asset Management, LLC ($453.4 million). In all, 715 institutions reported $8.1 billion of SNY in their 13F filings.
All SNY fund holdersFinancial highlights
Full financials- Revenue, FY2025
- €43.63B
- Revenue growth
- +6.2%
- Net income, FY2025
- €7.81B
- Net margin
- 17.9%
- Free cash flow, FY2025
- €7.21B
- Cash
- €7.66B
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
Latest news
25 items- FDAFDA Approval for INFILBRAY issued to GENZYME CORP A SANOFI COSubmission status for GENZYME CORP A SANOFI CO's drug INFILBRAY (ORIG-1) with active ingredient VENGLUSTAT has changed to 'Approval' on 11/18/2026. Application Category: NDA, Application Number: 221144, Application Classification: Type 1 - New Molecular Entity
- PRSanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patientsAgreement paves the way for newly diagnosed, transplant-ineligible patients fighting multiple myeloma to access first-line treatment Sarclisa® through provincial and territorial cancer treatment formulary listings.TORONTO, Nov. 16, 2026 /CNW/ -- Sanofi today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa® (isatuximab) intravenous (IV) in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the first-line treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
- FDAFDA Approval for CHILDREN'S ALLEGRA HIVES issued to CHATTEM SANOFISubmission status for CHATTEM SANOFI's drug CHILDREN'S ALLEGRA HIVES (SUPPL-53) with active ingredient FEXOFENADINE HYDROCHLORIDE has changed to 'Approval' on 11/10/2026. Application Category: NDA, Application Number: 020872, Application Classification: Labeling
- FDAFDA Approval for RIFADIN issued to SANOFI AVENTIS USSubmission status for SANOFI AVENTIS US's drug RIFADIN (SUPPL-40) with active ingredient RIFAMPIN has changed to 'Approval' on 11/10/2026. Application Category: NDA, Application Number: 050627, Application Classification: Labeling
- FDAFDA Approval for CHILDREN'S ALLEGRA ALLERGY issued to CHATTEM SANOFISubmission status for CHATTEM SANOFI's drug CHILDREN'S ALLEGRA ALLERGY (SUPPL-53) with active ingredient FEXOFENADINE HYDROCHLORIDE has changed to 'Approval' on 11/10/2026. Application Category: NDA, Application Number: 020872, Application Classification: Labeling
- FDAFDA Approval for ALLEGRA ALLERGY issued to CHATTEM SANOFISubmission status for CHATTEM SANOFI's drug ALLEGRA ALLERGY (SUPPL-53) with active ingredient FEXOFENADINE HYDROCHLORIDE has changed to 'Approval' on 11/10/2026. Application Category: NDA, Application Number: 020872, Application Classification: Labeling
- FDAFDA Approval for ALLEGRA HIVES issued to CHATTEM SANOFISubmission status for CHATTEM SANOFI's drug ALLEGRA HIVES (SUPPL-53) with active ingredient FEXOFENADINE HYDROCHLORIDE has changed to 'Approval' on 11/10/2026. Application Category: NDA, Application Number: 020872, Application Classification: Labeling
- FDAFDA Approval for ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION issued to CHATTEM SANOFISubmission status for CHATTEM SANOFI's drug ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION (SUPPL-27) with active ingredient FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE has changed to 'Approval' on 11/06/2026. Application Category: NDA, Application Number: 021704, Application Classification: Labeling
- ANALYSTSanofi upgraded by BNP Paribas ExaneBNP Paribas Exane upgraded Sanofi from Neutral to Outperform
- SECSEC Form 13F-HR filed by Sanofi13F-HR - Sanofi (0001121404) (Filer)
- SECSEC Form 6-K filed by Sanofi6-K - Sanofi (0001121404) (Filer)
- PRSanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory seasonNuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in 10 provinces and one territory for the fall 2026-2027 respiratory seasonA protein-based, non-mRNA vaccine that has demonstrated high efficacy against symptomatic COVID-19 in clinical trialsAvailability underscores Sanofi's commitment to public health and vaccine innovation in CanadaTORONTO, Oct. 28, 2026 /CNW/ -- Sanofi Canada is pleased to announce that Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in all 10 provinces and the Yukon for the 2026-2027 season through provincial respiratory programs and most private insurers. N
- SECSEC Form 6-K filed by Sanofi6-K - Sanofi (0001121404) (Filer)
- PRScionxBio Announces Collaboration to Develop Long-Acting xRNA TherapeuticsScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ:SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s proprietary TERA® platform.This agreement brings together the global expertise of Sanofi’s mRNA Center of Excellence, with ScionxBio’s TERA platform. This collaboration rep
- PRSanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory CareSanofi to work with provinces, territories, and federal drug programs to support patient access through public drug plansTORONTO, Oct. 15, 2026 /CNW/ -- Sanofi today announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and Sanofi with a signed Letter of Intent (LOI) for Dupixent for four additional indications: atopic dermatitis (AD) in pediatric patients, prurigo nodularis (PN), severe chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Sanofi looks forward to working with public payers to support access for eligible patients."This agreement with the pCPA is an important step forward i
- PRAI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost
- ANALYSTWolfe Research initiated coverage on SanofiWolfe Research initiated coverage of Sanofi with a rating of Peer Perform
- PRSanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination optionsTowns shares why protecting his health remains a priority and encourages informed conversations about COVID-19 vaccinationThe campaign highlights NUVAXOVID, the only FDA-approved protein-based, non-mRNA COVID-19 vaccineMORRISTOWN, N.J., Oct. 2, 2026 /PRNewswire/ -- Sanofi has partnered with 2026 NBA Champion Karl-Anthony Towns to help raise awareness about the importance of COVID-19 vaccination among those eligible dur
- SECSEC Form 6-K filed by Sanofi6-K - Sanofi (0001121404) (Filer)
- SECSEC Form 6-K filed by Sanofi6-K - Sanofi (0001121404) (Filer)
- PRSanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investmentThe $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soilBuilt in partnership with the Government of Canada, the Province of Ontario, and the City of Toronto to bolster the country's vaccine biomanufacturing capabilities and support Canada's national response to future flu pandemicsThe facility will manufacture Fluzone® High-Dose, Sanofi's flu vaccine indicated for adults 65 years of age and olderTORONTO, Sept. 16, 2026 /CNW/ -- Sanofi today inaugurated the Charles Best Building, a flu vaccine manufacturing facility that will manufacture Sanofi's Fluzone® High-Dose influenza vaccine. This new manufacturing facility also offers industrial scale capa
- PRSanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effectsThe campaign serves up COVID-19 prevention education, including details about NUVAXOVID™ and its established tolerabilityMORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi and USA Pickleball are teaming up to launch "Serve Up Protection," a campaign to educate older adults about COVID-19 and NUVAXOVID (COVID-19 Vaccine, Adjuvanted), the only protein-based, non-mRNA COVID-19 vaccine approved by the US Food and Drug Administration (FDA). "Serve Up Protection" aims to reach people during the respiratory season
- ANALYSTRBC Capital Mkts initiated coverage on SanofiRBC Capital Mkts initiated coverage of Sanofi with a rating of Sector Perform
- PRA Micro-Cap Biotech Just Cleared a Milestone Most Never ReachAUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at
- PRSanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infectionBEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, a leading cause of hospitalization among babies under 1 year of ageCampaign encourages parents to talk to their baby's doctor about helping protect their baby against serious RSV lung infection with BEYFORTUS, the #1 prescribed RSV immunization for babiesMORRISTOWN, N.J., Sept. 8, 2026 /PRNewswire/ -- Sanofi is partnering with Emmy Award-winning actress, entrepreneur and mom Keke Palmer to help e
Hiring
Nov 22, 2026Sanofi lists 1,426 open roles on its careers site as of Nov 22, 2026.
- Open roles
- 1,426
Counted daily from Sanofi's careers site.
SNY rankings
- Other19(73%)
- SEC Filings4(15%)
- Analyst3(12%)
Our reporting on SNY
- FDA approves Sanofi's Infilbray, the first drug for Type 3 Gaucher brain symptomsAnalysis · Nov 19, 2026 · 7 min read

- FDA approves Regeneron's Livsayis, the first siRNA drug for myasthenia gravis, dosed every three monthsAnalysis · Nov 19, 2026 · 6 min read

- Health Canada clears two Moderna flu vaccines for adults 50+, but only mFLUSIVA has efficacy data and no launch date or price is setAnalysis · Nov 5, 2026 · 6 min read

Sanofi (SNY) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for SNY, including 10 press releases and news items, 2 SEC filings and 1 analyst rating. The most recent was published Nov 19, 2026.
SNY FAQ
10 questionsWhat does Sanofi do?
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis...What is SNY revenue?
Sanofi (SNY) reported €43.63B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 6.2% from the year before.Is SNY profitable?
Yes. Sanofi earned €7.81B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.9%.How much cash and debt does SNY have?
Sanofi reported €7.66B in cash and cash equivalents and €18.59B of debt on its most recent balance sheet in SEC filings.Is Sanofi (SNY) hiring?
Sanofi lists 1,426 open roles on its careers site as of Nov 22, 2026.Where does SNY stock trade?
Sanofi (SNY) is listed on NASDAQ.What sector and industry is SNY in?
Sanofi operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SNY?
Across the last 8 analyst actions on Sanofi, there was 1 upgrade and 4 downgrades. The most recent action was from BNP Paribas Exane: Outperform on 2026-11-09. Recent price targets cluster around $50.00.What companies are similar to SNY?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare SNY side-by-side with any of them on Quantisnow.How can I track SNY on Quantisnow?
Quantisnow aggregates Sanofi's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNY to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change